Evaluation of the clinical safety and efficacy of iobitridol (Xenetix) in intravenous urography

The aim of this study is to report on the clinical safety and diagnostic efficacy of iobitridol (Xenetix(R)) in intravenous urography compared to iohexol (Omnipaque(R)) or iopamidol (Iopamiro(R)). A total of 120 patients underwent intravenous urography (ivu); 60 received Xenetix and 60 either Omnipaque (30 patients) or Iopamiro (30 patients) according to the center where they were treated. Clinical safety was assessed by the reporting of adverse events and diagnostic efficacy was evaluated. Warmth sensation was the most commonly reported adverse event. Two cases of nausea and vomiting were reported. Concerning diagnostic efficacy, 72-74% of the ivu examinations were rated good or excellent by the physician. These studies confirm that Xenetix is a suitable contrast agent for ivu.